Japan relies almost entirely on China for the APIs of β-lactam antibiotics. These drugs are essential for treating infectious diseases…
HOME > REGULATORY
REGULATORY
- LDP Members Voice Mixed Opinions on Active Recommendation for HPV Vaccines
June 3, 2014
- TPP Talks over IP Rights Hitting Snag: Cabinet
June 3, 2014
- MHLW Partially Agrees with Gov’t Panel’s Reason for Creation of New Mixed Care Rule
June 2, 2014
- Fiscal System Council Renews Call for Annual NHI Price Revision, MHLW Still Guarded
June 2, 2014
- PAFSC’s First Committee Backs Approval of LEO Pharma’s Ointment for Psoriasis Vulgaris, Shire Japan’s Gaucher’s Disease Drug
June 2, 2014
- MHLW Announces Addition of 9 APIs/11 Products to NHI Price List Including Takeda’s Takelda
June 2, 2014
- Government Panel Officially Proposes to Relax Current Mixed Care Rule
May 30, 2014
- Chuikyo to Assess Cost-Effectiveness of 5 Listed Drugs, Industry Leery of Price Cuts
May 29, 2014
- Pharmaceuticals and Medical Devices Safety Information Calls for Proper Use of Schizophrenia Treatment Xeplion
May 29, 2014
- Integrated Guidelines Will Apply to “Research” Conducted by the Media as Well: MHLW
May 29, 2014
- J-ADNI Data Falsification “Unacceptable” If True: MHLW
May 28, 2014
- Approval for Remicade Biosimilar Products Reported to PAFSC’s Second Committee
May 28, 2014
- CRC Training Program Presented to Panel on Clinical Research Promotion
May 27, 2014
- Diet Enacts Japanese NIH-Related Bills
May 26, 2014
- MHLW to Discuss Setting Rules on OTC Switching of Diagnostics at Panel on In Vitro Diagnostics
May 23, 2014
- PAFSC’s First Committee to Review LEO Pharma’s Psoriasis Drug on May 30
May 22, 2014
- Collaborations with PMDA, Prefectures Crucial in PIC/S: MHLW
May 22, 2014
- Risk Management Plans for 8 APIs Published Since April 2013; Will Be Required for Approval of New Drugs and Biosimilars Starting October 1, 2014
May 22, 2014
- Kyowa Kirin Workers’ Clinical Study Misconduct “Utterly Unacceptable”: Minister
May 21, 2014
- MHLW, MOF, Cabinet Office to Come to Agreement on Once-yearly NHI Price Revision by End May
May 21, 2014
ページ
Your company’s employer brand is your reputation as an employer and is crucial in attracting top talent. Some reputations are just not good; they may or not be deserved. That is just the perception in the market. Years ago there…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…